Upcoming Phase 2 Trial to Evaluate DPX-Survivac with Keytruda in Ovarian, Other Solid Tumors

Upcoming Phase 2 Trial to Evaluate DPX-Survivac with Keytruda in Ovarian, Other Solid Tumors
IMV will soon launch a Phase 2 trial to examine the potential of its lead candidate DPX-Survivac in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in five solid tumor types. The study is expected to include at least 200 patients with bladder, liver, ovarian, or non-small cell lung (NSCLC) cancers, as well as tumors positive for the microsatellite instability

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *